Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders
Executive Summary
Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.
You may also be interested in...
US FDA’s Woodcock ‘Managing As If She’s Been Commissioner,’ Not Afraid To Act, CBER Director Says
Peter Marks says Acting Commissioner Janet Woodcock’s tenure running the FDA has been no different than if a permanent commissioner were in place.
Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope
HHS Inspector General’s timeline means Congress won’t have findings to use during upcoming user fee renewal debate; ‘review’ is not an ‘investigation’ which could come with potentially more damning legal consequences for the agency.
Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?